Vosevi is intended as a follow-up treatment for adults with chronic hepatitis C virus genotypes 1 through 6 who have mild or no cirrhosis.
The fixed-dose combination tablet combines Gilead’s two previously approved hepatitis C treatments Sovaldi and Epclusa, along with a new drug, voxilaprevir.
More articles on supply chain:
Herbal coffee recalled for containing erectile dysfunction drug ingredien
Puma Biotech earns FDA approval for breast cancer drug
A supply chain expert on what your performance dashboard is missing
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
